✦ LIBER ✦

Adrenalectomy and hypophysectomy in advanced prostatic carcinoma

✍ Scribed by Gustavo Reynoso; Gerald P. Murphy

Publisher: John Wiley and Sons
Year: 1972
Tongue: English
Weight: 376 KB
Volume: 29
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(197204)29:4<941::aid-cncr2820290440>3.0.co;2-l

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Hypophysectomy in the treatment of disse

Hypophysectomy in the treatment of disseminated prostate carcinoma

✍ Gerald D. Silverberg 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 437 KB 👁 2 views

Medical and surgical adrenalectomy in pa

Medical and surgical adrenalectomy in patients with advanced breast carcinoma

✍ H. H. Newsome; Peter W. Brown; Jose J. Terz; Walter Lawrence Jr. 📂 Article 📅 1977 🏛 John Wiley and Sons 🌐 English ⚖ 366 KB 👁 1 views

Clinical effect of aminoglutethimide, me

Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma

✍ Joseph R. Drago; Richard J. Santen; Allan Lipton; Thomas J. Worgul; Harold A. Ha 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB 👁 1 views

Transphenoidal hypophysectomy in the man

Transphenoidal hypophysectomy in the management of carcinoma of the prostate

✍ Joseph A. Smith Jr; Richard G. Middleton; Harmon J. Eyre; Theodore S. Roberts 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 333 KB 👁 2 views

Fifteen consecutive patients with progressive metastatic prostate cancer who had failed primary endocrine therapy underwent surgical pituitary ablation by transphenoidal hypophysectomy. Eleven patients showed subjective improvement with reduced pain postoperatively. No patient had any evidence of an

Buserelin as primary therapy in advanced

Buserelin as primary therapy in advanced prostatic carcinoma

✍ Cary A. Presant; Mark S. Soloway; Sol S. Klioze; John W. Kosola; Alun L. Yakabow 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 369 KB 👁 1 views

Tamoxifen in advanced prostatic carcinom

Tamoxifen in advanced prostatic carcinoma. A dose escalation study

✍ Frank M. Torti; Bert L. Lum; Richard Lo; Fuad Freiha; Linda Shortliffe 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 431 KB 👁 1 views

Patients with advanced prostatic carcinoma who had received minimal or no prior therapy were treated with tamoxifen citrate in escalating doses from 10 to 50 mg orally twice a day. Twenty-nine courses were evaluated in 17 patients. Entry was limited to patients with measurable sites of disease. Ther